MMEDF News and Press, Mind Medicine From 01/07/21

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand Canada NewsWire Bolsters Cash on Hand to CAD $183.0m (USD $144.4m ) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

Palm Beach, FL – January 6, 2021 – In the few places where cannabis is legal, it can be incredibly lucrative. In 2019, the nascent worldwide cannabis sector pumped out approximately $15 billion in sales. By 2024, that number is expected to triple. Not bad for an industry that,...

Compass Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression. Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and...

It’s time for your Daily Hit of cannabis financial news for December 15, 2020. On the Site MindMed Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) entered into an agreement with Canaccord Genuity Corp. to purchase, on a bought deal basis an aggregate...

Mind Medicine ([[MMEDF]] -14.0%) agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity; underwriter has agreed to purchase 18.2M units at C$4.40/unit for gross proceeds of C$80.1M.Underwriters granted 30-day option to purchase up to an addition...

Mind Medicine ([[MMEDF]] -10.3%) has entered into an agreement with Canaccord Genuity Corp., on behalf of a syndicate of underwriters to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 11,364,000 units of Mind Medicine at a price of C$4.40/U...

Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) entered into an agreement with Canaccord Genuity Corp. to purchase, on a bought deal basis an aggregate of 11,364,000 units of the company at a price of C$4.40 per unit for gross proceeds of C$50 million . the company...

MindMed Announces $50 Million Bought Deal Public Offering /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./ NEW YORK , Dec....

COMPASS Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression. Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and...

MindMed ([[MMEDF]] +33.9%) has completed a pre-IND (Investigational New Drug) meeting with FDA regarding the development of lysergic acid diethylamide ((LSD)) assisted therapy for an anxiety disorder. The company intends to open the IND with the FDA in August 2021, with a Phase 2b t...